Vistagen

About Vistagen

Vistagen is a neuroscience-focused company dedicated to pioneering a new class of intranasal product candidates called 'pherines.' Their mission is to develop and commercialize innovative treatments for psychiatric and neurological disorders, leveraging nose-to-brain neurocircuitry to establish new standards of care for conditions like anxiety and depression affecting millions globally.

Products & Services

Fasedienol (PH94B):A treatment candidate for Social Anxiety Disorder.

AV-101:A product candidate in development for neurological disorders (specific indications not detailed in content).

Specialties

Nose-to-Brain Neurocircuitry Intranasal Product Candidates (Pherines) Psychiatric Disorders Treatment Neurological Disorders Treatment Social Anxiety Disorder Major Depressive Disorder

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2023-10-02 FD: 2023-10-02	8 investors

Underwritten Offering Latest

2023-10-02

$100.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Shawn K. Singh

President, Chief Executive Officer and Director

C

Cindy Anderson

Chief Financial Officer

J

Joshua Prince

Chief Operating Officer

E

Elissa Cote

Chief Corporate Development Officer

R

Reid Adler

Chief Legal Officer

A

Allen (Jo) Cato, III

Senior Vice President, Integrated Drug Development

View 31 more team members with Pro

Unlock Full Team Directory

Recent News

Vistagen Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised